Cargando…
Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database
INTRODUCTION: Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls. METHODS: This r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163909/ https://www.ncbi.nlm.nih.gov/pubmed/33929715 http://dx.doi.org/10.1007/s13555-021-00538-4 |
_version_ | 1783701003768430592 |
---|---|
author | Meyers, Kristin J. Silverberg, Jonathan I. Rueda, Maria Jose Goodloe, Robert Pierce, Evangeline J. Deberdt, Walter Brinker, Dennis R. |
author_facet | Meyers, Kristin J. Silverberg, Jonathan I. Rueda, Maria Jose Goodloe, Robert Pierce, Evangeline J. Deberdt, Walter Brinker, Dennis R. |
author_sort | Meyers, Kristin J. |
collection | PubMed |
description | INTRODUCTION: Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls. METHODS: This retrospective study used claims data from the IBM Watson MarketScan(®) Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases to identify adults aged 18 years or older with AD. Incidence rates (IR) per 100 person-years (PY) of VTE were reported for three cohorts: overall AD, moderate-to-severe AD, and non-AD controls matched by age, sex, and calendar time to the overall cohort. Cox proportional hazards regression was used to estimate hazard ratios (HR) for VTE risk. RESULTS: Overall, 198,685 patients with AD were identified. Crude VTE IRs were 0.24 for AD overall, 0.31 for moderate-to-severe AD, and 0.25 for non-AD controls. VTE risk was similar in patients with AD vs. non-AD controls (partially adjusted HR 1.00, 95% confidence interval [CI] 0.92, 1.09). VTE risk was greater in patients with moderate-to-severe AD vs. non-AD controls in partially adjusted models (HR 1.24, 95% CI 1.13, 1.36), but not after adjustment for healthcare use and VTE risk factors (HR 0.95, 95% CI 0.85, 1.07). CONCLUSIONS: AD was not an independent risk factor for VTE, and the risk of VTE among patients with AD was low. These findings provide valuable context for understanding VTE risk among patients with AD, which is particularly relevant as advanced therapies for the treatment of moderate to severe AD, such as janus kinase inhibitors, become available. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00538-4. |
format | Online Article Text |
id | pubmed-8163909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-81639092021-06-17 Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database Meyers, Kristin J. Silverberg, Jonathan I. Rueda, Maria Jose Goodloe, Robert Pierce, Evangeline J. Deberdt, Walter Brinker, Dennis R. Dermatol Ther (Heidelb) Original Research INTRODUCTION: Atopic dermatitis (AD) is associated with risk factors for venous thromboembolism (VTE). However, the risk of VTE among this population is unknown. The aim of this study was to assess the risk of VTE among adults with AD and compare the risk vs. matched non-AD controls. METHODS: This retrospective study used claims data from the IBM Watson MarketScan(®) Commercial Claims and Encounters, Medicare Supplemental, and Medicaid databases to identify adults aged 18 years or older with AD. Incidence rates (IR) per 100 person-years (PY) of VTE were reported for three cohorts: overall AD, moderate-to-severe AD, and non-AD controls matched by age, sex, and calendar time to the overall cohort. Cox proportional hazards regression was used to estimate hazard ratios (HR) for VTE risk. RESULTS: Overall, 198,685 patients with AD were identified. Crude VTE IRs were 0.24 for AD overall, 0.31 for moderate-to-severe AD, and 0.25 for non-AD controls. VTE risk was similar in patients with AD vs. non-AD controls (partially adjusted HR 1.00, 95% confidence interval [CI] 0.92, 1.09). VTE risk was greater in patients with moderate-to-severe AD vs. non-AD controls in partially adjusted models (HR 1.24, 95% CI 1.13, 1.36), but not after adjustment for healthcare use and VTE risk factors (HR 0.95, 95% CI 0.85, 1.07). CONCLUSIONS: AD was not an independent risk factor for VTE, and the risk of VTE among patients with AD was low. These findings provide valuable context for understanding VTE risk among patients with AD, which is particularly relevant as advanced therapies for the treatment of moderate to severe AD, such as janus kinase inhibitors, become available. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-021-00538-4. Springer Healthcare 2021-04-30 /pmc/articles/PMC8163909/ /pubmed/33929715 http://dx.doi.org/10.1007/s13555-021-00538-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Meyers, Kristin J. Silverberg, Jonathan I. Rueda, Maria Jose Goodloe, Robert Pierce, Evangeline J. Deberdt, Walter Brinker, Dennis R. Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title | Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title_full | Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title_fullStr | Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title_full_unstemmed | Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title_short | Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database |
title_sort | risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a us administrative claims database |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163909/ https://www.ncbi.nlm.nih.gov/pubmed/33929715 http://dx.doi.org/10.1007/s13555-021-00538-4 |
work_keys_str_mv | AT meyerskristinj riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT silverbergjonathani riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT ruedamariajose riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT goodloerobert riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT pierceevangelinej riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT deberdtwalter riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase AT brinkerdennisr riskofvenousthromboembolismamongpatientswithatopicdermatitisacohortstudyinausadministrativeclaimsdatabase |